Search - tctmd.com

Displaying 301 - 320 of 461

Sort: Relevancy | Date

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

News Daily News

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

Alison Palkhivala

April 11, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ISC 2017

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Todd Neale

February 24, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds

Todd Neale

December 19, 2016

News Daily News

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

Todd Neale

December 14, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

Advertisement

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

One in Five Acute MI Patients Drop Statins Within 2 Years

Midlife Vascular Risk Factors Linked to Amyloid Plaques in Alzheimer’s

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Early Statin Therapy Fails to Boost Acute Stroke Outcomes, but Trial Methods Questioned

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content